At this year’s annual meeting of the American Society of Gene and Cell Therapy (ASGCT), French biotechnology company EG 427 will share recent advances in the development of its recombinant, ...
This, based on the unique ability of our non-replicative HSV-1 vectors to deliver genetic medicines in a potentially safe, re-dosable and cost-effective way.” “ The treatment of our first patient in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results